Emory University
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
PRIMARY OBJECTIVE: I. To determine progression free survival of twenty-eight patients with platinum-resistant ovarian cancer treated with atovaquone. SECONDARY OBJECTIVES: I. To determine clinical benefit rate (complete response, partial response or stable disease) at six months. II. To determine overall survival. III. To quantitate the on-target STAT3 inhibitory effect of atovaquone on STAT3-dependent gene transcription. IV. To quantitate changes of the tumor immune infiltrate by inhibition of STAT3 with atovaquone. OUTLINE: Patients receive atovaquone orally (PO) on study. Patients al…
Inclusion Criteria: * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy * Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * There will be no limitations on number of prior lines of therapy * Trial is open to non-English speaking patients * Trial is open to patients referred from community practice Exclusion Criteria: * Patients who are \< 18 years old * Patients who are pregnant or breastfeeding (due to cancer of their repro…
Given PO
Undergo biopsy
Undergo CT
Undergo paracentesis
Arctuva estimate
Verify or correct the compensation shown for this listing.